arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

INSMED Inc

INSM
$131.15 ▼ -1.46 (-1.10%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
65 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

INSMED Inc faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $28.3B
Dividend Yield
Revenue Growth 229.6%
Op. Margin -50.1%
ROIC -12.4%
FCF / Share $-1.05
Trailing P/E
Price / Book 40.3x
FCF Yield
Debt / Equity 0.78
info Valuation on last close. End-of-day price, Aug 7, 2026.

65-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$305.96M
↑ +229.6%
Net Income Profit after all expenses
$-163.56M
↑ +36.3%
Operating Margin Operating profit as % of sales
-50.1%
↑ +58.7% 0th
FCF / Share Free cash flow per share
$-1.05
↑ +30.2%
Long-Term Debt Long-term obligations
$546.77M
— 0.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns
4
Financial Health
32
Cash Quality
51

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 65 quarters